Enwei Pharmaceutical Co., Ltd. (SHE:301331)
China · Delayed Price · Currency is CNY 21.84
+0.24 (1.11%)
At close: Sep 30, 2026
Enwei Pharmaceutical Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 377.01 | 362.31 | 370.27 | 236.12 | 341.58 | 64.25 |
Trading Asset Securities | 97.8 | 171.28 | 144.72 | 157.16 | 236.56 | 14.4 |
Cash & Short-Term Investments | 474.82 | 533.58 | 515 | 393.28 | 578.14 | 78.65 |
Cash Growth | -11.26% | 3.61% | 30.95% | -31.97% | 635.07% | 1.59% |
Accounts Receivable | 218.64 | 309.72 | 296.53 | 265 | 245.28 | 192.91 |
Other Receivables | 4.29 | 3.06 | 3.69 | 3.99 | 4.17 | 3.98 |
Receivables | 222.93 | 312.78 | 300.22 | 268.98 | 249.45 | 196.89 |
Inventory | 130.64 | 101.1 | 115.55 | 107.37 | 104.65 | 110.01 |
Other Current Assets | 28.08 | 28 | 21.27 | 17.23 | 25.06 | 28.21 |
Total Current Assets | 856.47 | 975.46 | 952.04 | 786.86 | 957.29 | 413.77 |
Property, Plant & Equipment | 269.92 | 264.9 | 246.55 | 231.12 | 240 | 241.77 |
Long-Term Investments | 28 | 20 | 0.37 | 0.37 | 0.35 | 0.42 |
Goodwill | 100.55 | 100.55 | 100.55 | 100.55 | 100.55 | 100.55 |
Other Intangible Assets | 109.32 | 117.28 | 133.37 | 148.04 | 42.08 | 47.45 |
Long-Term Deferred Tax Assets | 4.33 | 3.89 | 4.64 | 3.05 | 1.8 | 1.74 |
Long-Term Deferred Charges | 11.72 | 13.45 | 8.7 | 10.68 | 16.83 | 18.28 |
Other Long-Term Assets | 57.36 | 55.13 | 58.3 | 56.81 | 47.18 | 45.11 |
Total Assets | 1,438 | 1,551 | 1,505 | 1,337 | 1,406 | 869.09 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Accounts Payable | 48.02 | 56.48 | 49.49 | 30.94 | 36.88 | 33.64 |
Accrued Expenses | 105.14 | 136.32 | 132.83 | 141.69 | 141.02 | 128.52 |
Current Portion of Long-Term Debt | 10 | 185.07 | 10.09 | - | - | - |
Current Portion of Leases | 1.88 | 1.53 | 1.27 | 0.88 | - | - |
Current Income Taxes Payable | 0.85 | 5.19 | 6.52 | 10.21 | 11.23 | 8.19 |
Current Unearned Revenue | 21.9 | 19.73 | 24.61 | 14.01 | 28.15 | 16.15 |
Other Current Liabilities | 15.65 | 50.68 | 13.6 | 12.04 | 10.31 | 12.73 |
Total Current Liabilities | 203.44 | 454.99 | 238.42 | 209.77 | 227.58 | 199.22 |
Long-Term Debt | 190 | - | 185 | - | - | - |
Long-Term Leases | 0.92 | 1.44 | 1.52 | 0.46 | - | - |
Long-Term Unearned Revenue | 7.47 | 8.79 | 9.96 | 11.92 | 14.05 | 15.88 |
Long-Term Deferred Tax Liabilities | 13.98 | 12.64 | 11.96 | 12.17 | 11.45 | 11.74 |
Total Liabilities | 415.8 | 477.86 | 446.86 | 234.31 | 253.08 | 226.84 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Common Stock | 102.89 | 102.89 | 102.89 | 70.14 | 70.14 | 52.6 |
Additional Paid-In Capital | 632 | 630.96 | 638.71 | 671.51 | 664.63 | 239.22 |
Retained Earnings | 320.1 | 373.35 | 375.25 | 392.32 | 418.23 | 350.43 |
Treasury Stock | -33.12 | -34.4 | -59.18 | -30.78 | - | - |
Total Common Equity | 1,022 | 1,073 | 1,058 | 1,103 | 1,153 | 642.25 |
Shareholders' Equity | 1,022 | 1,073 | 1,058 | 1,103 | 1,153 | 642.25 |
Total Liabilities & Equity | 1,438 | 1,551 | 1,505 | 1,337 | 1,406 | 869.09 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Total Debt | 202.79 | 188.04 | 197.88 | 1.34 | - | - |
Net Cash (Debt) | 272.02 | 345.54 | 317.12 | 391.94 | 578.14 | 78.65 |
Net Cash Growth | -20.66% | 8.96% | -19.09% | -32.21% | 635.07% | 1.59% |
Net Cash Per Share | 2.60 | 3.35 | 3.14 | 3.81 | 6.85 | 1.01 |
Filing Date Shares Outstanding | 101.88 | 101.88 | 101.08 | 100.99 | 103.8 | 77.85 |
Total Common Shares Outstanding | 101.88 | 101.84 | 101.08 | 102.76 | 103.8 | 77.85 |
Working Capital | 653.03 | 520.47 | 713.62 | 577.09 | 729.7 | 214.55 |
Book Value Per Share | 10.03 | 10.53 | 10.46 | 10.74 | 11.11 | 8.25 |
Tangible Book Value | 811.99 | 854.97 | 823.74 | 854.59 | 1,010 | 494.25 |
Tangible Book Value Per Share | 7.97 | 8.40 | 8.15 | 8.32 | 9.73 | 6.35 |
Buildings | 286.53 | 289.03 | 289.03 | 287.63 | 275.1 | 274.06 |
Machinery | 330.77 | 315.25 | 301.77 | 302.77 | 271.99 | 263.51 |
Construction In Progress | 66.46 | 64.46 | 40.37 | 8.82 | 35.68 | 23.84 |